1. Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial. Issue 1 (January 2022) Authors: Verma, Subodh; Dhingra, Nitish K; Butler, Javed; Anker, Stefan D; Ferreira, Joao Pedro; Filippatos, Gerasimos; Januzzi, James L; Lam, Carolyn S P; Sattar, Naveed; Peil, Barbara; Nordaby, Matias; Brueckmann, Martina; Pocock, Stuart J; Zannad, Faiez; Packer, Milton; Packer, M; Anker, S; Butler, J; ... Journal: Lancet Issue: Volume 10:Issue 1(2022) Page Start: 35 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Rivaroxaban or aspirin for patent foramen ovale and embolic stroke of undetermined source: a prespecified subgroup analysis from the NAVIGATE ESUS trial. Issue 12 (December 2018) Authors: Kasner, Scott E; Swaminathan, Balakumar; Lavados, Pablo; Sharma, Mukul; Muir, Keith; Veltkamp, Roland; Ameriso, Sebastian F; Endres, Matthias; Lutsep, Helmi; Messé, Steven R; Spence, J David; Nedeltechev, Krassen; Perera, Kanjana; Santo, Gustavo; Olavarria, Veronica; Lindgren, Arne; Bangdiwala, S... Journal: Lancet neurology Issue: Volume 17:Issue 12(2018) Page Start: 1053 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗